C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
1.730
+0.260 (17.69%)
Jun 6, 2025, 4:00 PM - Market closed
C4 Therapeutics Stock Forecast
CCCC's stock price has decreased by -65.05% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 3 professional analysts, the 12-month price target for C4 Therapeutics stock ranges from a low of $4.00 to a high of $20. The average analyst price target of $12 forecasts a 593.64% increase in the stock price over the next year.
Price Target: $12.00 (+593.64%)
Analyst Consensus: Buy
* Price targets were last updated on Dec 19, 2024.
Analyst Ratings
The average analyst rating for C4 Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 3 | 3 | 3 | 3 | 3 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold → Buy Upgrades $8 → $12 | Hold → Buy | Upgrades | $8 → $12 | +593.64% | Dec 19, 2024 |
| Stephens & Co. | Stephens & Co. | Hold Initiates $4 | Hold | Initiates | $4 | +131.21% | Nov 18, 2024 |
| BMO Capital | BMO Capital | Buy Reiterates $20 | Buy | Reiterates | $20 | +1,056.07% | Aug 6, 2024 |
| Wells Fargo | Wells Fargo | Hold Maintains $7 → $8 | Hold | Maintains | $7 → $8 | +362.43% | May 9, 2024 |
| Stifel | Stifel | Strong Buy Maintains $13 → $14 | Strong Buy | Maintains | $13 → $14 | +709.25% | May 9, 2024 |
Financial Forecast
Revenue This Year
21.86M
from 35.58M
Decreased by -38.58%
Revenue Next Year
21.54M
from 21.86M
Decreased by -1.45%
EPS This Year
-1.84
from -1.52
EPS Next Year
-1.61
from -1.84
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 38.1M | 42.0M | 36.8M | ||
| Avg | 21.9M | 21.5M | 21.2M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 7.1% | 92.2% | 70.6% | ||
| Avg | -38.6% | -1.5% | -1.6% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.60 | -1.16 | -0.69 | ||
| Avg | -1.84 | -1.61 | -1.44 | ||
| Low | -2.02 | -2.18 | -2.27 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.